Regeneus Revenue and Competitors
Estimated Revenue & Valuation
- Regeneus's estimated annual revenue is currently $1.6M per year.
- Regeneus's estimated revenue per employee is $155,000
Employee Data
- Regeneus has 10 Employees.
- Regeneus grew their employee count by -23% last year.
Regeneus's People
| Name | Title | Email/Phone |
|---|
Regeneus Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Regeneus?
Regeneus Ltd (ASX: RGS) is a clinical-stage biotech company developing innovative first-in-class stem cell, exosome and immuno-oncology therapies that address significant unmet medical needs.
keywords:N/AN/A
Total Funding
10
Number of Employees
$1.6M
Revenue (est)
-23%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Regeneus News
2022-04-20 - Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 ...
Mesoblast; Roslin Cells; Regeneus; ReNeuron Group; International Stem Cell Corporation; Takeda. The report explores the regional and country...
2022-04-17 - Canine Stem Cell Therapy Market Analysis, Research Study ...
VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos. Report overview:.
2022-04-17 - Veterinary Vaccine Market Is Booming Worldwide 2022-2028 ...
Veterinary Vaccine Market Is Booming Worldwide 2022-2028 | Aratana Therapeutics, Inc., Regeneus Ltd., Morphogenesis, Inc.
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.3M | 46 | N/A | N/A |
#2 | $13.6M | 97 | 23% | N/A |
#3 | $26.2M | 97 | -7% | N/A |
#4 | $16.5M | 114 | 7% | N/A |
#5 | $19.9M | 122 | -9% | N/A |
